Pfizer’s TUKYSA boosts front-line outcomes, extending progression-free survival in HER2+ metastatic breast cancer
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Subscribe To Our Newsletter & Stay Updated